Insider buying last 90 days
No open-market insider purchases were filed for ALKS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ALKS insider filing, plotted on the chart in Gekko.Open ALKS in Gekko
NASDAQ: ALKS
Alkermes (ALKS) Stock Analysis & Forecast
Sep 28 close
$40.15−0.70 (−1.7%)
Gekko Brief
AI summaryThis week's news centers on ALKS 7290, Alkermes' investigational oral ADHD drug, with a Phase 1b trial showing symptom improvements across dose levels in healthy volunteers and adults, described as the first proof-of-concept for the orexin-modulating drug in ADHD. Coverage notes the study was not powered to establish statistical significance over placebo, and a larger trial would be needed to confirm the findings. Separate coverage discusses LUMRYZ's potential expansion into idiopathic hypersomnia following positive Phase 3 results, which could add a new indication alongside existing commercial infrastructure.
Shares close at $40.15, down 1.7%, sitting below the 50-day average of $47.88 but above the 200-day average of $38.85. Trailing returns show a 1-month decline of 17.9% and a 3-month decline of 23.6%, against a 6-month gain of 36.6% and a 1-year gain of 48%. The GekkoIndex reads 75.7, placing the stock in the Buying zone, and price sits 13.7% below Gekko Fair Value of $46.52.
The next earnings date falls on 28 October 2026, before the open, 29 days out and beyond a typical 20-trading-day holding window; the prior report showed an EPS beat with a -8.3% reaction. Over the last 90 days, Congress shows 2 buys and 0 sells, while the last 30 days show 1 unusual options signal with put premium of $390,780 and no call premium. Seasonality over the next 20 trading days has averaged -4.7% across 5 years, rising in 2 of them. Consensus among 13 firms includes 9 buy, 3 hold and 1 sell ratings, with a consensus target of $56.56.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Alkermes price vs fair value
Close $40.15200-day averageGekko Fair Value $46.52
Alkermes quick facts
- Market cap
- $6.74B
- P/E ratio
- 107.5
- Forward P/E
- 133.3
- EPS, TTM
- $0.38
- Revenue, TTM
- $1.67B
- Profit margin
- 4%
- Dividend yield
- —
- Beta
- 0.26
- Volume
- 2.08M avg 2.02M
- 1-year return
- +48.0%
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±6.4%
- 50-day average
- $47.88
- 200-day average
- $38.85
- Next earnings
- Oct 28 before open
- Shares outstanding
- 167.8M
Alkermes swing-trade checklist
Alkermes scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $40.15 sits between the 50-day ($47.88) and 200-day ($38.85) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
75.7, Buying
Reading 75.7 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
13.7% below
Price is 13.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneymixed
Mixed
Last 90 days: Congress 2 buys / 0 sales. Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 29 days
Next report Oct 28, 2026, 29 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−4.7% on average
From this point in the calendar, the next 20 trading days averaged −4.7% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Alkermes stock chart and price history
Alkermes closed at $40.15 on Sep 28, 2026, +48.0% over the past year, inside a 52-week range of $27.00 to $55.67.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −17.9%
- 3 months
- −23.6%
- 6 months
- +36.6%
- 1 year
- +48.0%
The full ALKS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ALKS in Gekko
Follow Alkermes through every session
Put ALKS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ALKS in GekkoFree for 7 days. No credit card required.
About Alkermes
Alkermes develops and sells pharmaceutical products aimed at treating conditions such as opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder. It is known for a set of marketed treatments including ARISTADA and ARISTADA INITIO for schizophrenia, VIVITROL for alcohol and opioid dependence, LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for cataplexy or excessive daytime sleepiness in pediatric patients. Alongside these, the company continues work on clinical and preclinical candidates targeting neurological disorders.
Beyond its own product line, Alkermes licenses proprietary technology platforms to other firms, allowing them to develop, manufacture, and bring products to market. It also maintains collaboration agreements with several Janssen Pharmaceutica entities. Its work spans patients and partners in the United States, Ireland, and other international markets.
The company was founded in 1987 and is based in Dublin, Ireland. Its shares are listed on the NASDAQ under the ticker ALKS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- alkermes.com
Alkermes GekkoIndex: the smart money zone
Alkermes’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 75.7, in the Buying zone, up 1.9 points over five sessions.
75.7Buying
Up 1.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 36 | −0.3% | +12.3% | ||
| Accumulation | 224 | +0.7% | +3.0% | ||
| Neutral | 359 | +0.4% | +0.3% | ||
| Distribution | 51 | +0.6% | +4.1% | ||
| Selling | 2 | Too few readings yet | |||
Average ALKS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the ALKS price, zone by zone.Track ALKS in Gekko
Is Alkermes stock overvalued? Gekko Fair Value
Alkermes trades 13.7% below Gekko Fair Value of $46.52, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Alkermes shares are worth, recalculated every trading day.
$46.52
Gekko Fair Value, Sep 29, 2026
13.7% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ALKS in Gekko
Alkermes insider and Congress trading
No open-market insider purchases were filed for Alkermes, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Ray Cisneros House, CA, purchase | $15,001 - $50,000 | Sep 7 traded Jul 30 |
| Gilbert Ray Cisneros House, CA, purchase | $15,001 - $50,000 | Sep 7 traded Jul 29 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Alkermes has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2026
- $27.70M
- As a share of market cap
- 0.41%
From company filings.
Unusual options activity last 30 days
1signal, 0% of the flagged premium in calls.
Latest: Bullish flow on Sep 1, $391K in unusual premium.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold ALKS.
0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Alkermes earnings: next date and track record
Alkermes reports on Oct 28, 2026, before the open (29 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected before the open, 29 days away
- EPS estimate
- −$0.08
- Revenue estimate
- $463.5M
6 of 8reports beat the EPS estimate
±7.7%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 28, 2026 AI summary
- What they said
- Alkermes reported Q2 2026 results with CEO Richard Pops delivering his final earnings call before transitioning to Chairman. Key highlights include advancing alixorexton as the leading orexin 2 receptor agonist, demonstrating efficacy in narcolepsy type 1 and type 2 Phase 2 studies with sustained improvements up to nine months. Phase 3 narcolepsy enrollment is on track, ALKS 7290 is enrolling ADHD patients with Phase 1b data expected Q3, and ALKS 4510 targets MS/Parkinson's fatigue.
- Guidance
- Phase 3 narcolepsy program expected to complete enrollment next year. ALKS 7290 Phase 1b ADHD data expected by end of Q3 2026. ALKS 4510 fatigue Phase 2 initial data anticipated in 2027. Management projects meaningful clinical readouts across multiple programs in H2 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | $0.52 est −$0.04 | $496.0M est $457.4M | −8.3% |
| May 5, 2026 | $0.38 est −$0.04 | $392.9M est $363.1M | +3.4% |
| Feb 25, 2026 | $0.34 est $0.43 | $384.5M est $378.9M | −8.0% |
| Oct 28, 2025 | $0.65 est $0.39 | $394.2M est $356.9M | +5.8% |
| Jul 29, 2025 | $0.52 est $0.41 | $390.7M est $354.5M | +6.8% |
| May 1, 2025 | $0.13 est $0.25 | $306.5M est $302.9M | +10.5% |
| Feb 12, 2025 | $1.05 est $0.76 | $430.0M est $379.4M | +12.6% |
| Oct 24, 2024 | $0.73 est $0.71 | $378.1M est $381.4M | −6.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Alkermes stock forecast and analyst price targets
Analysts’ average 12-month price target for Alkermes is $56.56, +40.9% from the last close, from 13 firms rating the stock in the last 90 days.
$56.56consensus 12-month target, +40.9% from the last close
Now $40.15Avg $56.56
Low $38High $83
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Goldman Sachs | $50 | +24.5% |
| Sep 22 | Mizuho Securities | $65 | +61.9% |
| Sep 22 | RBC Capital | $56 | +39.5% |
| Sep 22 | Robert W. Baird | $61 | +51.9% |
| Sep 22 | Jefferies | $83 | +106.7% |
+12.3%average 20-day move after past Buying readings
−4.7%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Alkermes seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Alkermes averaged −4.7% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.4% | 5 of 5 |
| Next 10 trading days | +3.5% | 4 of 5 |
| Next 15 trading days | +0.7% | 2 of 5 |
| Next 20 trading days | −4.7% | 2 of 5 |
| Next 30 trading days | −1.9% | 3 of 5 |
For scale, ALKS’s typical 20-trading-day move in either direction is about 6.4%.
Alkermes market cap and key statistics
Alkermes’s market cap is $6.74B, with a P/E ratio of 107.5 and revenue of $1.67B over the last twelve months.
Valuation
- Market cap
- $6.74B
- P/E ratio
- 107.5
- Forward P/E
- 133.3
- EPS, TTM
- $0.38
- Gekko Fair Value
- $46.52
Trading
- Volume
- 2.08M
- Avg volume, 20 days
- 2.02M
- 52-week high
- $55.67
- 52-week low
- $27.00
- Shares outstanding
- 167.8M
Financials
- Revenue, TTM
- $1.67B
- Profit margin
- 4%
- Return on equity
- 3.9%
- Quarterly earnings growth, YoY
- −99.4%
Risk and income
- Beta
- 0.26
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±6.4%
Alkermes stock news this week
5 headlines about Alkermes from the past week, newest first, each linking to the publisher.
- Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?Insider Monkey, Sep 26
- Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin DriverSeeking Alpha, Sep 26
- Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290Zacks Investment Research, Sep 22
- How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly WonInvestors Business Daily, Sep 21
- Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)Business Wire, Sep 21
Alkermes peers
Alkermes’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Alkermes stock FAQ
What is Alkermes’s market cap?
Alkermes’s market cap is $6.74B at the Sep 28, 2026 close of $40.15, with 167.8M shares outstanding. The shares trade on a P/E ratio of 107.5.
What is the Alkermes stock forecast?
The consensus analyst 12-month price target for Alkermes is $56.56, +40.9% from the last close. Of the 13 firms that rated the stock in the last 90 days, 9 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Alkermes stock overvalued or undervalued?
On Gekko’s estimate Alkermes is undervalued: the Sep 28, 2026 close of $40.15 is 13.7% below Gekko Fair Value of $46.52. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Alkermes report earnings next?
Alkermes is expected to report on Oct 28, 2026, before the market opens (29 days away). Analysts expect earnings of −$0.08 per share on revenue of $463.5M. Alkermes beat the earnings estimate in 6 of its last 8 reports, moving 7.7% on average across the report.
What is Alkermes’s 52-week high and low?
Alkermes’s 52-week high is $55.67 and its 52-week low is $27.00; it closed at $40.15 on Sep 28, 2026, +48.0% over the past year.
Is Alkermes stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (trend and smart money) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Alkermes?
Gekko flagged 1 unusual options signal in Alkermes over the last 30 days, with $0 of flagged premium in calls and $391K in puts. The latest, bullish flow, was on Sep 1, 2026 with $391K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Alkermes the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.